Take­da flesh­es out CNS pact with pep­tide drug­mak­er, set­ting aside $3.5B in fu­ture mile­stones

One of a suite of drug­mak­ers look­ing to rein­vest in the neu­ro­science space, Take­da has been ag­gres­sive in sign­ing on new part­ners to help build up its pipeline in that space. But some­times the best part­ner is the one you al­ready have.

Take­da will set aside $3.5 bil­lion in fu­ture mile­stones and an undis­closed up­front pay­ment to build out its drug dis­cov­ery deal with Japan­ese pep­tide con­ju­gate mak­er Pep­tiDream, adding neu­rode­gen­er­a­tion to the part­ner­ship’s list of CNS tar­gets, the com­pa­nies said Tues­day.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER